Kyntheum

Brodalumab, the active ingredient in Kyntheum, is an interleukin‑17 receptor antagonist presented as a 210 mg/1 mL solution for injection for subcutaneous use. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients.

GNH USA supplies Kyntheum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing the EU‑approved biologic to qualified healthcare institutions. The company adheres to stringent quality standards and offers reliable cold‑chain logistics for this injectable biologic, ensuring product integrity from manufacture to delivery.

Brodalumab is employed to modulate the interleukin‑17 signaling cascade in the treatment of inflammatory skin disorders, primarily moderate to severe plaque psoriasis.

Plaque psoriasis: reduces skin lesions and improves quality of life in adults with moderate to severe disease. Refractory plaque psoriasis: offers clinical benefit for patients who have not responded adequately to conventional systemic therapies. Psoriasis‑related quality of life: leads to significant reductions in itching, scaling and psychological burden associated with severe disease.

Brodalumab may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild redness, swelling or discomfort at the injection site. - Upper respiratory tract infection: symptoms such as sore throat, nasal congestion or cough. - Headache: transient mild to moderate headache. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Suicidal ideation or behavior: new or worsening thoughts of self‑harm. - Serious infections: including pneumonia or cellulitis requiring medical attention. - Neutropenia: low neutrophil count that may increase infection risk.

Before initiating brodalumab therapy, several precautionary measures should be considered to ensure patient safety.

- Infection screening: assess for active infections before initiating therapy. - Immunization: administer required vaccines prior to treatment; avoid live vaccines during therapy. - Monitoring: perform regular complete blood counts to detect neutropenia. - Psychiatric assessment: evaluate for depression or suicidal thoughts before and during treatment. - Pregnancy and lactation: avoid use; safety in pregnancy and breastfeeding is unknown. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Brodalumab can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Live vaccines: administration while on brodalumab can cause uncontrolled infection. - Concurrent biologics: using other IL‑17 or TNF inhibitors may increase immunosuppression risk.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may enhance infection susceptibility; monitor closely. - Cyclosporine or other immunosuppressants: combined effect on immune system warrants careful observation. - Antifungal agents metabolized by CYP450: monitor for potential altered drug levels.